Lexeo Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
Condensed Statements of Cash Flows
(Unaudited, in thousands)
| Six Months Ended June 30, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| Cash flows from operating activities: | |||
| Net loss | $(46,063) | $(58,759) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Reduction in the carrying amount of ROU assets, operating | 795 | 729 | |
| Reduction in the carrying amount of ROU assets, finance | 160 | 160 | |
| Stock-based compensation expense | 8,445 | 6,768 | |
| Depreciation and amortization expense | 147 | 122 | |
| Non-cash gain on long-term investment in preferred stock | - | (3,390) | |
| Amortization of premium (accretion of discount) on investments in U.S. Treasury securities, net | (21) | 46 | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (221) | (2,566) | |
| Accounts payable | (768) | 13,507 | |
| Accrued expenses and other current liabilities | (403) | (4,822) | |
| Lease liabilities, operating | (814) | (721) | |
| Lease liabilities, finance | 2 | (9) | |
| Net cash used in operating activities | (38,741) | (48,935) | |
| Cash flows from investing activities: | |||
| Proceeds from sales or maturities of investments | 53,735 | 31,900 | |
| Purchases of investments | (11,969) | (55,366) | |
| Purchase of property and equipment | (42) | (108) | |
| Net cash provided by (used in) investing activities | 41,724 | (23,574) | |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock under the ATM Program, gross | 25,000 | - | |
| Offering costs incurred and paid to third parties in association with the ATM Program | (804) | - | |
| Proceeds from exercise of common warrants | 2,446 | - | |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement Offering, gross | - | 79,999 | |
| Third-party commissions and offering costs incurred upon May 2025 Private Placement Offering | - | (6,917) | |
| Proceeds from exercise of stock options | 329 | - | |
| Proceeds from common stock issuances under 2023 ESPP | 143 | 170 | |
| Payments on finance leases | (263) | (281) | |
| Net cash provided by financing activities | 26,851 | 72,971 | |
| Net change in cash, cash equivalents and restricted cash | 29,834 | 462 | |
| Cash, cash equivalents and restricted cash at beginning of period | 66,248 | 38,266 | |
| Cash, cash equivalents and restricted cash at end of period | $96,082 | $38,728 | |
| Supplemental disclosure of non-cash activities | |||
| Unrealized gain (loss) on investments in U.S. Treasury securities | $(486) | $90 | |
| Offering costs reclassified from other current assets to additional paid-in capital | $645 | $ | - |
| Amounts reclassified from deposit liabilities to additional paid-in capital upon the vesting of early-exercised stock options previously subject to repurchase | $2 | $25 | |
| Unpaid offering costs included in accounts payable and accrued expenses | $4 | $905 | |
| Unpaid property and equipment purchases included in accounts payable | $87 | $101 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.